Illuminating a path forward for Tobacco Nation: Projected impacts of recommended policies on geographic disparities

Duration:

60 Minutes

Webinar Speakers

Emily Donovan, MPH

Senior Research Associate, Truth Initiative Schroeder Institute

Emily Donovan is a Senior Research Associate at Truth Initiative in Washington, DC. In her role, Emily focuses on researching and evaluating tobacco control policies – particularly, how state and local jurisdictions can use tobacco control policies to reduce tobacco use and health disparities. Emily has led studies characterizing the comprehensiveness of state and local policies regulating tobacco retailers. Additionally, she has contributed to studies evaluating the impacts of federal, state, and local tobacco control policies such as flavored tobacco sales restrictions and taxes. Emily holds a Master of Public Health degree in Health Behavior from the University of North Carolina at Chapel Hill.

Michael Maciosek, PhD

Senior Research Investigator, HealthPartners Institute

Dr. Michael Maciosek is a health economist and Senior Research Investigator at HealthPartners Institute in Minneapolis, Minnesota. He has conducted clinical interventions and public policy analyses across a broad spectrum of preventive services. Dr. Maciosek’s current work focuses on the analyses of tobacco control policy using the HealthPartners Institute’s ModelHealthTM: Tobacco microsimulation model, which he curates. He led studies in collaboration with ClearWay Minnesota to conduct simulations of the impact of Minnesota’s success in reducing the prevalence in tobacco use and currently leads an NIH-funded study to determine the population health effects of electronic nicotine delivery systems under alternative tobacco policy scenarios. Dr. Maciosek has also led economic analyses within NIH-funded studies of depression, cardiovascular disease and cancer care, policy analyses for Centers for Disease Control and Prevention, and a decision analysis for the US Preventive Services Task Force. Before joining HealthPartners, Dr. Maciosek held a Prevention Effectiveness Fellowship at the CDC, where he supported the Task Force on Community Preventive Services and the Committee on Clinical Preventive Service Priorities.

Webinar Objectives
  1. Describe “Tobacco Nation,” a group of 13 states in the South and Midwest of the United States which have disproportionately high rates of smoking compared to the rest of the US.
  2. Describe the expected trajectory of geographic disparities between Tobacco Nation and the rest of the US over 20 years in the absence of policy change (status quo scenario).
  3. Describe expected trajectory of geographic disparities over 20 years if Tobacco Nation states were to implement increased cigarette taxes and tobacco control expenditures (policy scenario).
  4. Compare status quo and policy scenarios to understand the potential impacts of strengthening tobacco control policies in Tobacco Nation.
Instructions for CME/CEU Credit

CME/CEUs are no longer available for this webinar. Credit will be available again in January for the recorded version of this webinar.

 

Certificates of Attendance

Click here to generate a certificate of attendance for participating on this webinar.

 

ACCME Accreditation

The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.

Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.

Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.

California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA category 1 CreditTM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.

California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditTM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.

California Behavioral Science Professionals: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.

Course meets the qualifications for 1.0 hour of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences. Provider # 64239.

ACCREDITATION FOR CALIFORNIA ADDICTION COUNSELORS

The UCSF office of continuing medical education is accredited by the California Consortium of Addiction Programs and Professionals (CCAPP), to provide continuing education credit for California addiction counselors. UCSF designates this live, virtual activity, for a maximum of 1.0 CCAPP credit. Addiction counselors should claim only the credit commensurate with the extent of their participation in the activity. Provider number: 7-20-322-0722.

 

Disclosures

This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Anita Browning, Christine Cheng, Brian Clark, Emily Donovan, MPH, Pamela Ling, MD, MPH, Michael Maciosek, PhD, Jennifer Matekuare, Ma Krisanta Pamatmat, MPH, Catherine Bonniot Saucedo, and Aria Yow, MA.

Additional Resources